Journal
NEUROCHEMICAL RESEARCH
Volume 35, Issue 3, Pages 495-502Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11064-009-0086-6
Keywords
Parkinson's disease; Glial cell line-derived neurotrophic factor; Lentivirus; Gene therapy; Bone marrow stromal cells; Lactacystin
Categories
Funding
- Natural Science Foundation of Shanghai Municipality [03ZR14016]
Ask authors/readers for more resources
The potential value of glial cell line-derived neurotrophic factor (GDNF) in treating Parkinson's disease (PD) remains controversial. In order to evaluate the therapeutic effect of GDNF-engineered bone marrow stromal cells (BMSCs) in parkinsonian rat model, GDNF-BMSCs and LacZ-BMSCs were transplanted into striatum and followed by Lactacystin lesioning at median forebrain bundles 1 week later. We observed that the intrastriatal transplantation of GDNF-BMSCs could significantly rescue the dopaminergic neurons from lactacystin-induced neurotoxicity with regard to behavioral recovery, tyrosine hydroxylase level in nigra and striatum, and striatal dopamine level. We interpret the outcomes that intrastriatal transplantation of GDNF-BMSCs might be beneficial in the treatment of PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available